Pharmacovigilance and patient safety: The interplay of nursing, diagnosis, and medical records
Keywords:
Pharmacovigilance, Elderly, Digital Health Technologies, Adverse Drug Reactions, Real-World DataAbstract
Background _ Pharmacovigilance, as defined by the World Health Organization, involves the scientific and operational activities aimed at identifying, evaluating, comprehending, and mitigating the adverse effects or any issues associated with medicines or vaccines. It plays a crucial role in recognizing negative effects of medications that may escape detection during clinical trials. This scrutiny is particularly vital for older individuals, who are frequently excluded from clinical studies due to their comorbidities and polypharmacy, resulting in treatment regimens that extend beyond the duration of these trials. Aim of Work – The aim of this narrative review is to explore novel approaches in pharmacovigilance studies focused on medications for elderly individuals. It specifically highlights how advancements in digital health technologies, electronic health records, and real-world health data can enhance the detection and evaluation of adverse effects in this sensitive population. Methods – The review employs a narrative approach, synthesizing current literature on the utilization of digital health technologies and available health data in pharmacovigilance. It emphasizes recent developments in electronic health records and real-world data analytics, assessing how these tools can facilitate the monitoring of medication safety among older patients.
Downloads
References
- World Health Organization. What is pharmacovigilance? 2023. https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance
- Shah H, Nagi J, Khare S, Hassan H, Siu A. Limiting factors in implementing pharmacovigilance principles in the elderly. Cureus. 2023; 15(3):e36899. doi:10.7759/cureus.36899
- Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450–mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013; 47(3): 324-332. doi:10.1345/aph.1R621
- Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015; 13(1): 74. doi:10.1186/s12916-015-0322-7
- Yadesa T, Kitutu F, Deyno S, Ogwang P, Tamukong R, Alele P. Prevalence, characteristics and predicting risk factors of adverse drug reactions among hospitalized older adults: a systematic review and meta-analysis. SAGE Open Med. 2021; 9: 1-14. doi:10.1177/20503121211039099
- Tan Y, Papez V, Chang W, Mueller S, Denaxas S, Lai A. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43895 trials and 5685738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev. 2022; 3(10): e674-e679. doi:10.1016/S2666-7568(22)00186-6
- Hilmer S, Gnjidic D, Le Couteur D. Thinking through the medication list. Appropriate prescribing and deprescribing in robust and frail older patients. Aust Fam Physician. 2012; 41(12): 924-928.
- Roughead E, Pratt N, Parfitt G, et al. Effect of an ongoing pharmacist service to reduce medicine-induced deterioration and adverse reactions in aged-care facilities (nursing homes): a multicentre, randomised controlled trial (the ReMInDAR trial). Age Ageing. 2022; 51: 1-9.
- Lim R, Kalisch Ellett L, Widagdo I, Pratt N, Roughead E. Analysis of anticholinergic and sedative medicine effects on physical function, cognitive function, appetite and frailty: a cross-sectional study in Australia. BMJ Open. 2019; 9(9):e029221. doi:10.1136/bmjopen-2019-029221
- Kalisch Ellett L, Pratt N, Ramsay E, Barratt J, Roughead E. Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia. J Am Geriatr Soc. 2014; 62(10): 1916-1922. doi:10.1111/jgs.13054
- Kalisch Ellett L, Pratt N, Ramsay E, Sluggett J, Barratt J, Roughead E. Central nervous system-acting medicines and risk of hospital admission for confusion, delirium, or dementia. J Am Med Dir Assoc. 2016; 17(6): 530-534. doi:10.1016/j.jamda.2016.02.008
- Kalisch Ellett L, Pratt N, Barratt J, Rowett D, Roughead E. Risk of medication-associated initiation of oxybutynin in elderly men and women. J Am Geriatr Soc. 2014; 62(4): 690-695. doi:10.1111/jgs.12741
- European Medicines Agency. Note for guidance on planning pharmacovigilance activities (CPMP/ICH/5716/03). In ICH Topic E 2 E Pharmacovigilance Planning (Pvp). 2005, EMEA: London.
- Gould A. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf. 2003; 12(7): 559-574. doi:10.1002/pds.771
- Hazell L, Shakir S. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006; 29(5): 385-396. doi:10.2165/00002018-200629050-00003
- Lasser K, Allen P, Woolhandler S, Himmelstein D, Wolfe S, Bor D. Timing of new black box warnings and withdrawals for prescription medications. Jama. 2002; 287(17): 2215-2220. doi:10.1001/jama.287.17.2215
- Wahab I, Pratt N, Kalisch L, Roughead E. Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. Drug Saf. 2014; 37(1): 53-64. doi:10.1007/s40264-013-0124-9
- Awad A, Trenfield S, Pollard T, et al. Connected healthcare: improving patient care using digital health technologies. Adv Drug Deliv Rev. 2021; 178:113958. doi:10.1016/j.addr.2021.113958
- Lavertu A, Vora B, Giacomini K, Altman R, Rensi S. A new era in pharmacovigilance: toward real-world data and digital monitoring. Clin Pharmacol Ther. 2021; 109(5): 1197-1202. doi:10.1002/cpt.2172
- Australian Institute of Health and Welfare (AIHW). Digital health. Accessed 31 January 2024. 2022. https://www.aihw.gov.au/reports/australias-health/digital-health
- Australian Government Therapeutic Goods Administration. Adverse drug reaction reporting using best practice: installing the ADR reporting template. 2023. https://www.tga.gov.au/resources/resource/guidance/adverse-drug-reaction-reporting-using-best-practice-installing-adr-reporting-template
- Oosterhuis I, Taavola H, Tregunno P, et al. Characteristics, quality and contribution to signal detection of spontaneous reports of adverse drug reactions via the WEB-RADR mobile application: a descriptive cross-sectional study. Drug Saf. 2018; 41(10): 969-978. doi:10.1007/s40264-018-0679-6
- Innovative Medicines Initiative. WEB-RADR Med safety app. 2023. https://web-radr.eu/mobile-apps/med-safety/
- Hood C, Sikka N, Manaoat C, Mossburg SE. Remote patient monitoring. PSNet Patient Safety Network. March 15, 2023. https://psnet.ahrq.gov/perspective/remote-patient-monitoring#:~:text=Remote%20patient%20monitoring%20(RPM)%20is,oximeters%2C%20and%20blood%20glucose%20meters
- Feinberg J, Cameron K, Lapane K, Allsworth J. The use of GRAM™ software to improve patient safety in nursing facilities. Consult Pharm. 2004; 5(5): 398-413. doi:10.4140/TCP.n.2004.398
- Parfitt G, Post D, Kalisch Ellett L, et al. A cross-sectional assessment of the relationship between sedative medication and anticholinergic medication use and the movement behaviour of older adults living in residential aged care. Peer J. 2020; 8:e9605. doi:10.7717/peerj.9605
- Delio J, Catalanotti J, Marko K, et al. Integrating adverse event reporting into a free-text mobile application used in daily workflow increases adverse event reporting by physicians. Am J Med Qual. 2019; 35(5): 374-379. doi:10.1177/1062860619891995
- Li R, Curtain C, Bereznicki L, Zaidi S. Community pharmacists' knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. Int J Clin Pharmacol. 2018; 40(4): 878-889. doi:10.1007/s11096-018-0700-2
- National Health Performance Authority, Healthy Communities. Frequent GP attenders and their use of health services in 2012–13. 2015. NHPA: Canberra.
- NAB Health. NAB pharmacy survey 2021. Consumer attitudes and behaviours: trust, importance, visitation, patient satisfaction and scope of practice. 2021. NAB: Sydney.
- Margraff F, Bertram D. Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014; 37(6): 409-419. doi:10.1007/s40264-014-0162-y
- Australian Government Australian Digital Health Agency. Safe, seamless and secure: evolving health and care to meet the needs of modern Australia. Australia's National Digital Health Strategy. 2017. Australian Digital Health Agency: Canberra.
- Australian Government Australian Communications and Media Authority. Communications and media in Australia. The digital lives of older Australians. 2021, ACMA: Canberra.
- Lapane K, Hughes C, Daiello L, Cameron K, Feinberg J. Effect of a pharmacist-led multicomponent intervention focusing on the medication monitoring phase to prevent potential adverse drug events in nursing homes. J Am Geriatr Soc. 2011; 59(7): 1238-1245. doi:10.1111/j.1532-5415.2011.03418.x
- Lim R, Dumuid D, Parfitt G, et al. Using wrist-worn accelerometers to identify the impact of medicines with anticholinergic or sedative properties on sedentary time: a 12-month prospective analysis. Maturitas. 2023; 172: 9-14. doi:10.1016/j.maturitas.2023.03.006
- Andrade A, Lim R, Kelly T, Parfitt G, Pratt N, Roughead E. Wrist accelerometer temporal analysis as a prognostic tool for aged care residents: a sub-study of the ReMInDAR trial. J Am Geriatr Soc. 2023; 71(4): 1124-1133. doi:10.1111/jgs.18181
- Clarke C, Sniehotta F, Vadiveloo T, Donnan P, Witham M. Association between objectively measured physical activity and opioid, hypnotic, or anticholinergic medication use in older people: data from the physical activity cohort Scotland study. Drugs Aging. 2018; 35(9): 835-842. doi:10.1007/s40266-018-0578-7
- Logie H, Hogan R, Peut A. Longitudinal studies of ageing: implications for future studies. AIHW cat. no. AGE 42. 2004. Australian Institute of Health and Welfare: Canberra.
- Bennett S, Song X, Mitnitski A, Rockwood K. A limit to frailty in very old, community-dwelling people: a secondary analysis of the Chinese longitudinal health and longevity study. Age Ageing. 2013; 42(3): 372-377. doi:10.1093/ageing/afs180
- Hirsch C, Buzkova P, Robbins J, Patel K, Newman AB. Predicting late-life disability and death by the rate of decline in physical performance measures. Age Ageing. 2012; 41(2): 155-161. doi:10.1093/ageing/afr151
- Briggs R, Kenny R, Kennelly S. Does baseline hypotension predict incident depression in a cohort of community-dwelling older people? Data from the Irish longitudinal study on ageing (TILDA). Age Ageing. 2017; 46(4): 648-653. doi:10.1093/ageing/afx033
- Martin F, Ortuno R. Longitudinal studies of ageing: from insights to impacts: commentary to accompany themed collection on longitudinal studies. Age Ageing. 2019; 48(4): 481-485. doi:10.1093/ageing/afz028
Published
How to Cite
Issue
Section
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.